Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

"Intervenção Educativa para a Tokofobia em Mulheres Grávidas" (TOKO-EDU)

5 de novembro de 2026 atualizado por: Delta University for Science and Technology

Changes in Tokophobia Awareness, Fear of Childbirth, Coping Strategies, and Quality of Life Following Structured Educational Sessions Among Pregnant Women: A Quasi-Experimental Single-Group Pretest-Posttest Study

This quasi-experimental single-group pretest-posttest study examined immediate within-participant differences in tokophobia awareness, fear of childbirth, reported coping-strategy use, and quality of life among 50 pregnant women attending the antenatal outpatient clinics of Soad Kafafi Hospital, 6th of October City, Giza, Egypt.

Participants attended a standardized program comprising ten face-to-face sessions delivered twice weekly over five weeks. Each session lasted approximately 45-60 minutes, including orientation, baseline assessment, educational activities, review, and post-intervention evaluation.

Outcomes were assessed using the researcher-developed Tokophobia Awareness Questionnaire (TAQ), an Arabic translation of the Fear of Childbirth Questionnaire (FCQ), the Jalowiec Coping Scale (JCS), and WHOQOL-BREF. Baseline measures were completed before educational content was delivered. Post-intervention assessment took place immediately after the final session on the same day. No longer-term follow-up was conducted.

The absence of a comparison group prevents causal attribution of the observed differences to the educational sessions.

Visão geral do estudo

Descrição detalhada

The study used a quasi-experimental single-group pretest-posttest design. Fifty pregnant women participated in the main study. Five separate women participated in pilot testing and were excluded from the main-study sample and analysis.

The main-study participants were divided into ten groups of five. The same educator, specializing in obstetric and gynecological health nursing, delivered the standardized program separately to each group. Other research-team members administered and collected the outcome questionnaires.

Each participant attended ten sessions over five consecutive weeks, with two sessions per week and approximately 45-60 minutes per session. Session 1 covered study orientation and procedures. Session 2 included baseline assessment, completed before delivery of educational content. Sessions 3-8 addressed tokophobia-related knowledge, childbirth preparation, coping strategies, stress management, communication, and professional and social support. Session 9 covered review and reinforcement. Session 10 included final reinforcement and immediate post-intervention assessment.

The TAQ assessed factual knowledge and awareness of tokophobia. The FCQ assessed self-reported fear of childbirth rather than establishing a clinical diagnosis of tokophobia. The JCS assessed frequency of coping-strategy use, and WHOQOL-BREF assessed self-reported quality of life across four domains.

No single primary outcome was prospectively designated. The continuous FCQ total score was prioritized for interpretation during manuscript revision. Analyses are exploratory because the study lacked a comparison group and multiple tests were conducted without adjustment.

Tipo de estudo

Intervencional

Inscrição (Real)

50

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Giza Governorate
      • Cairo, Giza Governorate, Egito, 12566
        • Soad Kafafi Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Pregnant women aged 18 years or older.
  • Attending the antenatal outpatient clinics at the study setting.
  • Willing to participate and provide informed consent.

Exclusion Criteria:

- Diagnosed severe or acute psychiatric disorders that could interfere with study participation.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Educational Intervention Group

Pregnant women attended a standardized ten-session educational program delivered face-to-face in groups of five, twice weekly over five weeks. Each session lasted approximately 45-60 minutes, including orientation, assessment, educational activities, review, and evaluation. Educational content addressed tokophobia awareness, childbirth preparation, coping strategies, relaxation, stress management, and available professional and social support.

A structured educational program designed to provide information about tokophobia, its causes, symptoms, and management, along with training on psychological coping strategies and supportive techniques to enhance maternal well-being.

Outros nomes:
  • Programa de Educação sobre Tokofobia

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Fear of Childbirth Questionnaire (FCQ) Total Score
Prazo: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the 20-item FCQ total score from baseline to immediate post-intervention assessment. Items are scored 0-3, with positively worded items reverse-scored. Total scores range from 0 to 60; higher scores indicate greater fear of childbirth. The Arabic translation used in this study underwent preliminary linguistic and cultural adaptation.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Tokophobia Awareness Questionnaire (TAQ) Total Score
Prazo: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the researcher-developed 23-item TAQ total score from baseline to immediate post-intervention assessment. Correct responses are scored 1 and incorrect responses 0. Total scores range from 0 to 23; higher scores indicate greater factual knowledge and awareness of tokophobia.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.
Change in Jalowiec Coping Scale (JCS) Total Score
Prazo: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the 40-item JCS total score from baseline to immediate post-intervention assessment. Items are scored from 1 to 5, producing total scores ranging from 40 to 200. Higher scores indicate more frequent self-reported coping-strategy use.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.
Change in WHOQOL-BREF Domain Scores
Prazo: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Changes from baseline to immediate post-intervention assessment in the four WHOQOL-BREF domains: physical health, psychological health, social relationships, and environment. Each domain score is transformed to a 0-100 scale, with higher scores indicating better self-reported quality of life. The four domains are analyzed separately.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Basma W Elrefay, phd, Delta University for Science and Technology, Egypt

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de fevereiro de 2025

Conclusão Primária (Real)

10 de maio de 2025

Conclusão do estudo (Real)

15 de maio de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

4 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

4 de abril de 2026

Primeira postagem (Real)

13 de abril de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data (IPD) will not be made publicly available due to privacy, confidentiality, and ethical restrictions related to the study participants.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever